Interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-2, and arachidonic acid metabolites modulate IL-4-induced IgE synthesis similarly in healthy persons and in atopic dermatitis patients.
The role of cytokines and arachidonic acid metabolites in the regulation of IgE production in healthy persons and in atopic dermatitis patients with elevated IgE levels was studied. Interleukin-4 (IL-4) induced IgE production in peripheral blood mononuclear cells (PBMCs) of all donors, and no significant difference was found between the amounts of IgE produced by healthy persons and atopic dermatitis patients. Similarly, recombinant interferon (IFN)-alpha and IFN-gamma, as well as IL-2, inhibited IL-4-induced IgE production to a similar extent in both study groups. To evaluate the role of arachidonic acid (AA) metabolites in the regulation of IgE production, we added indomethacin, an inhibitor of the cyclooxygenase pathway, or nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase pathway, to IL-4-treated cultures. Both indomethacin and NDGA strongly inhibited IL-4-induced IgE production. They also inhibited IL-4-induced IgG4 synthesis. No significant difference in the amount of inhibition was found between the two study groups. We were unable to restore the NDGA-induced inhibition of IgE-production by adding leukotrienes B4, C4, D4, or 5-HETE to the NDGA-treated cultures. PGE2 also failed to restore the indomethacin-mediated inhibitory effect. Consequently, NDGA- and indomethacin-mediated inhibitory effects do not appear to be mediated by any single factor studied. Collectively, our results show IFNs and IL-2 to be similar in effect in the modulation of IL-4-induced IgE synthesis in healthy and atopic persons.(ABSTRACT TRUNCATED AT 250 WORDS)
Punnonen
J
J
Department of Medical Microbiology, Turku University, Finland.
Punnonen
K
K
Jansén
C T
CT
Kalimo
K
K
D000328:Adult; D001095:Arachidonic Acids / Q000494:pharmacology / Q000502:physiology*; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology / Q000502:physiology*; D003876:Dermatitis, Atopic / Q000276:immunology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007075:Immunoglobulin M / Q000032:analysis; D007213:Indomethacin / Q000494:pharmacology; D007370:Interferon Type I / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D011994:Recombinant Proteins
D001095:Arachidonic Acids; D016207:Cytokines; D007075:Immunoglobulin M; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D015847:Interleukin-4; D007073:Immunoglobulin E; D009637:Masoprocol; D007371:Interferon-gamma; D007213:Indomethacin